Patent №
US 6,564,092
Granted
2003-05-13
Filed 2000
Owner
HISAMITSU PHARMACEUTICAL CO., INC.
Lab
—
AI components
1
hardware
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
09445451
A transdermal or transmucosal drug delivery device excellent in terms of drug permeability and skin irritability and capable of reducing power consumption, is disclosed. An output control circuit (4) of an energization pattern controller (1) supplies a combined energization of pulse depolarized type energization and at least one of direct current type energization and pulse energization between an anode-side device (5) and a cathode-side device (6) of iontophoresis. The details of combination of energization in the output control circuit (4) is determined based on external setting of the energization pattern controller (1) or internal storage information.
AI classification
Ownership
HISAMITSU PHARMACEUTICAL CO., INC.
assignment · 107060131
Assignors
NAKAMURA, KATSUHIRO, KATAGAI, KAZUYA, INOUE, KAZUTAKA, HIGO, NARUHITO
On an employer assignment, the assignors are typically the inventors.